NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. More Details
Reasonable growth potential with adequate balance sheet.
Share Price & News
How has NeoGenomics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NEO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: NEO's weekly volatility (7%) has been stable over the past year.
7 Day Return
US Life Sciences
1 Year Return
US Life Sciences
Return vs Industry: NEO exceeded the US Life Sciences industry which returned 65.3% over the past year.
Return vs Market: NEO exceeded the US Market which returned 56.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is NeoGenomics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StWe Think That There Are More Issues For NeoGenomics (NASDAQ:NEO) Than Just Sluggish Earnings
2 months ago | Simply Wall StHow Much Are NeoGenomics, Inc. (NASDAQ:NEO) Insiders Taking Off The Table?
3 months ago | Simply Wall StIs NeoGenomics (NASDAQ:NEO) Weighed On By Its Debt Load?
Is NeoGenomics undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: NEO ($48.17) is trading above our estimate of fair value ($27.67)
Significantly Below Fair Value: NEO is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: NEO is poor value based on its PE Ratio (1253.7x) compared to the US Life Sciences industry average (43.2x).
PE vs Market: NEO is poor value based on its PE Ratio (1253.7x) compared to the US market (22.3x).
Price to Earnings Growth Ratio
PEG Ratio: NEO is poor value based on its PEG Ratio (16.2x)
Price to Book Ratio
PB vs Industry: NEO's PB Ratio (7.8x) is in line with the US Life Sciences industry average.
How is NeoGenomics forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NEO's forecast earnings growth (77.5% per year) is above the savings rate (2%).
Earnings vs Market: NEO's earnings (77.5% per year) are forecast to grow faster than the US market (18.6% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: NEO's revenue (12.3% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: NEO's revenue (12.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NEO's Return on Equity is forecast to be low in 3 years time (6%).
How has NeoGenomics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NEO has a large one-off gain of $4.9M impacting its December 31 2020 financial results.
Growing Profit Margin: NEO's current net profit margins (0.9%) are lower than last year (1.9%).
Past Earnings Growth Analysis
Earnings Trend: NEO has become profitable over the past 5 years, growing earnings by 45.9% per year.
Accelerating Growth: NEO's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: NEO had negative earnings growth (-47.6%) over the past year, making it difficult to compare to the Life Sciences industry average (7.4%).
Return on Equity
High ROE: NEO's Return on Equity (0.6%) is considered low.
How is NeoGenomics's financial position?
Financial Position Analysis
Short Term Liabilities: NEO's short term assets ($448.7M) exceed its short term liabilities ($73.2M).
Long Term Liabilities: NEO's short term assets ($448.7M) exceed its long term liabilities ($220.9M).
Debt to Equity History and Analysis
Debt Level: NEO's debt to equity ratio (24.8%) is considered satisfactory.
Reducing Debt: NEO's debt to equity ratio has reduced from 25.9% to 24.8% over the past 5 years.
Debt Coverage: NEO's debt is not well covered by operating cash flow (0.8%).
Interest Coverage: Insufficient data to determine if NEO's interest payments on its debt are well covered by EBIT.
What is NeoGenomics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NEO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NEO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NEO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NEO's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NEO's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Doug VanOort (65 yo)
Mr. Douglas M. VanOort, also known as Doug, has been the Chairman and Chief Executive Officer of NeoGenomics Inc. since October 28, 2009. Mr. VanOort has been the Executive Chairman and Chief Executive Off...
CEO Compensation Analysis
Compensation vs Market: Doug's total compensation ($USD3.65M) is below average for companies of similar size in the US market ($USD6.40M).
Compensation vs Earnings: Doug's compensation has been consistent with company performance over the past year.
Experienced Management: NEO's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: NEO's board of directors are considered experienced (6.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.6%.
NeoGenomics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: NeoGenomics, Inc.
- Ticker: NEO
- Exchange: NasdaqCM
- Founded: 2001
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$5.720b
- Shares outstanding: 116.94m
- Website: https://www.neogenomics.com
Number of Employees
- NeoGenomics, Inc.
- 12701 Commonwealth Drive
- Suite 9
- Fort Myers
- United States
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers te...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/12 22:42|
|End of Day Share Price||2021/04/12 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.